Spleen Stiffness Measurement Linked With Portal Hypertension in MPNs
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
Interferon Cuts Risk of MF—but Not Thrombosis—in Young Patients With MPNs
Molecular Response to Therapy Linked With Event-Free Survival in PV
Post Hoc Analysis Findings Offer Guidance for Anemia Management in Myelofibrosis: Pankit Vachhani, MD
Ruxolitinib Plus Anemia Supportive Care Maintains Efficacy in Myelofibrosis: Pankit Vachhani, MD
Next Steps for INCA33989 Focus on Dosing, Delivery, and Safety: John Mascarenhas, MD
Post-Hoc Analysis Evaluates Ruxolitinib Plus Anemia-Supportive Therapies in Myelofibrosis: Pankit Vachhani, MD
INCA33989 Shows Disease-Modifying Potential With Favorable Safety in Essential Thrombocythemia: John Mascarenhas, MD
Phase 1 Trials Assess Safety, Dosing of CAL-R Antibody for Essential Thrombocythemia: John Mascarenhas, MD
Rusfertide Offers Sustainable PV Management Strategy: Andrew Kuykendall, MD
Fatigue, Quality of Life Improve With Rusfertide: Andrew Kuykendall, MD
Rusfertide Cuts Phlebotomy Need in Polycythemia Vera: Andrew Kuykendall, MD
Reducing Polycythemia Vera–Associated Thrombotic Risk Through Iron Regulation
Options for MPN Treatment Are Expanding Rapidly With More on the Horizon
Treatment Differences for Younger vs Older Patients With MPNs
NCCN Guidelines for MPN Reflect New Drugs, Focus on Clinical Trials
Korean Study Finds DOAC Use “Seems Effective” in Patients With MPNs